
Biotechnology
NewLimit, founded by Coinbase’s CEO, raises $130M for age-reversing drugs
Biotech startup NewLimit, which is focused on extending healthy human lifespan through cellular reprogramming, has raised a $130 million Series B round led by Kleiner Perkins. The round also included new investors Nat Friedman, Daniel Gross, and Khosla Ventures, along with returning backers like Founders Fund, Dimension Capital, Elad Gil,